Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Return on Capital Employed (2016 - 2026)

Tandem Diabetes Care filings provide 12 years of Return on Capital Employed readings, the most recent being 29.48% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 1563.0% to 29.48% in Q4 2025 year-over-year; TTM through Dec 2025 was 29.48%, a 1563.0% decrease, with the full-year FY2025 number at 27.47%, down 1357.0% from a year prior.
  • Return on Capital Employed hit 29.48% in Q4 2025 for Tandem Diabetes Care, up from 31.5% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 4.06% in Q3 2021 to a low of 31.5% in Q3 2025.
  • Median Return on Capital Employed over the past 5 years was 19.46% (2024), compared with a mean of 15.63%.
  • Biggest five-year swings in Return on Capital Employed: crashed -2909bps in 2023 and later skyrocketed 1720bps in 2024.
  • Tandem Diabetes Care's Return on Capital Employed stood at 3.04% in 2021, then plummeted by -445bps to 10.49% in 2022, then tumbled by -196bps to 31.05% in 2023, then surged by 55bps to 13.85% in 2024, then plummeted by -113bps to 29.48% in 2025.
  • The last three reported values for Return on Capital Employed were 29.48% (Q4 2025), 31.5% (Q3 2025), and 30.8% (Q2 2025) per Business Quant data.